Merck licenses Chinese cancer drug

Merck licenses Chinese cancer drug, searching for next Keytruda blockbuster
In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from LaNova Medicines, a Shanghai-based firm, for $588 million upfront and as much as $2.7 billion in potential milestone payments.
Merck Snags Chinese Cancer Drug in Deal Worth Up to $3.3 Billion
Merck & Co. licensed an experimental cancer antibody from a closely held Chinese company in a deal worth $588 million upfront, plus as much as $2.7 billion in milestone payments.
Merck signs up to $3.3 bln cancer drug deal with China-based LaNova
Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and sell an experimental cancer drug, the two companies said on Thursday.
Merck to buy rights to Chinese cancer drug for up to $3.3B
Merck (MRK) stock will be in focus as company inks deal worth up to $3.3B to buy licensing rights to a cancer candidate called LM-299 from LaNova. Read more here.
Pharmalittle: We’re reading about a Merck deal, GSK cancer drug data, and more
In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company
Merck signs up to $3.3 billion cancer drug deal with China-based LaNova
Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and sell an experimental cancer drug, the two companies said on Thursday. The deal allows Merck to take over development of LaNova's LM-299,
BioPharma Dive17h
Merck, facing threat to Keytruda, buys into new kind of cancer immunotherapy
The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...
Yale Daily News1d
Yale spin-off company Modifi Bio acquired by Merck in multimillion dollar deal
What separates KL-50 from other chemotherapy drugs is its remarkable selectivity ... it was fundraising,” Lin told the News ...
FiercePharma18h
Merck joins American Lung Association in raising awareness of pulmonary arterial hypertension
As the rollout of its recently launched pulmonary arterial hypertension (PAH) drug Winrevair ramps up, Merck is continuing ...
pharmaphorum7d
FDA approves Merck’s Delstrigo and Pifeltro for HIV treatment
Merck, known as MSD outside the United ... HIV and their communities for the collaboration that made today’s approval possible.” Both drugs, administered orally once daily, are indicated ...
NBC Los Angeles14d
Merck tops earnings estimates on strong demand for Keytruda, new drugs even as HPV vaccine sales fall
Merck reported third-quarter revenue and adjusted earnings that topped expectations. The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its ...
Seeking Alpha20d
Merck Q3 Earnings Review: Solid Financials May Be Undermined By New Keytruda Threat
but lacks a ready-made Keytruda replacement. Investors should monitor R&D updates closely, as Merck's future hinges on new drug developments amid looming patent expirations. Keytruda is now ...